Literature DB >> 25547265

Colonization with extended-spectrum beta-lactamase-producing and carbapenemase-producing Enterobacteriaceae in international travelers returning to Germany.

Christoph Lübbert1, Laurentia Straube2, Claudia Stein3, Oliwia Makarewicz3, Stefan Schubert2, Joachim Mössner4, Mathias W Pletz3, Arne C Rodloff5.   

Abstract

Two hundred and twenty-five healthy German volunteers traveling to 53 different countries (mostly in Asia, Africa and South America) were enrolled in a prospective cohort study. Stool samples and data on potential travel-associated risk factors (such as type of travel, nutritional habits, occurrence of gastroenteritis) were collected before and after traveling. Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) and carbapenemase-producing Enterobacteriaceae (CPE) was performed using selective media (CHROMagar™ ESBL/CPE plates). Isolates with confirmed ESBL-phenotype were examined for the presence of blaCTX-M, blaTEM, blaSHV, and blaVIM, blaIMP, blaNDM, blaKPC, blaOXA-48 genes by PCR amplification and sequencing. Antimicrobial susceptibility testing was performed using conventional microbroth dilution. Pre-travel analysis of 205 fully evaluable participants revealed an ESBL-PE prevalence rate of 6.8% (14/205). Among 191 participants that were ESBL-negative before travel, 58 (30.4%) were colonized by ESBL-producing Escherichia coli, and 5 (8.6%) additionally carried ESBL-producing Klebsiella pneumoniae upon return. However, no carbapenem-resistant Enterobacteriaceae were detected. ESBL-genotyping revealed that 52/54 (96.6%) E. coli and 4/4 (100%) K. pneumoniae strains available for sequencing produced CTX-M enzymes, mostly CTX-M-15 (33/56, 58.9%), and 2/54 (3.7%) E. coli strains produced SHV-12 enzymes. Travel to India was associated with the highest ESBL-PE acquisition rate (11/15, 73.3%; p=0.015), followed by South East Asia (22/46, 47.8%; p=0.038). Evaluation of travel-associated risk factors demonstrated significance for the occurrence of gastroenteritis (p=0.011). Strictly practiced hand hygiene and exclusive consumption of packaged beverages showed no protective effect. The ESBL-PE persistence rate after 6 months was 8.6% (3/35). We conclude that global efforts are needed to address the further spread of ESBL-PE in the community. Active surveillance and contact isolation precautions may be recommended at admission to medical facilities especially for patients who traveled to India and South East Asia in the previous 6 months.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Active surveillance, Community; Antimicrobial resistance; CPE; CTX-M; ESBL

Mesh:

Substances:

Year:  2014        PMID: 25547265     DOI: 10.1016/j.ijmm.2014.12.001

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  53 in total

1.  Acquisition of multidrug-resistant bacteria and encoding genes among French pilgrims during the 2017 and 2018 Hajj.

Authors:  Van-Thuan Hoang; Thi-Loi Dao; Tran Duc Anh Ly; Frédérique Gouriet; Linda Hadjadj; Khadidja Belhouchat; Kamel Larbi Chaht; Saber Yezli; Badriah Alotaibi; Didier Raoult; Philippe Parola; Sophie Alexandra Baron; Vincent Pommier de Santi; Jean-Marc Rolain; Philippe Gautret
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-01-07       Impact factor: 3.267

2.  Large variation in ESBL-producing Escherichia coli carriers in six European countries including Russia.

Authors:  Sofia Ny; Roman Kozlov; Uga Dumpis; Petra Edquist; Kirsi Gröndahl-Yli-Hannuksela; Anna-Maria Kling; Danuta O Lis; Christoph Lübbert; Monika Pomorska-Wesołowska; Ivan Palagin; Aija Vilde; Jaana Vuopio; Jan Walter; Karin Tegmark Wisell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-10-18       Impact factor: 3.267

Review 3.  Travel and the Spread of Drug-Resistant Bacteria.

Authors:  Kevin L Schwartz; Shaun K Morris
Journal:  Curr Infect Dis Rep       Date:  2018-06-29       Impact factor: 3.725

4.  Environmental pollution with antimicrobial agents from bulk drug manufacturing industries in Hyderabad, South India, is associated with dissemination of extended-spectrum beta-lactamase and carbapenemase-producing pathogens.

Authors:  Christoph Lübbert; Christian Baars; Anil Dayakar; Norman Lippmann; Arne C Rodloff; Martina Kinzig; Fritz Sörgel
Journal:  Infection       Date:  2017-04-26       Impact factor: 3.553

Review 5.  The Traveling Microbiome.

Authors:  Mark S Riddle; Bradley A Connor
Journal:  Curr Infect Dis Rep       Date:  2016-09       Impact factor: 3.725

6.  Detection and epidemiology of carbapenemase producing Enterobacteriaceae in the Netherlands in 2013-2014.

Authors:  A L M Vlek; D Frentz; A Haenen; H J Bootsma; D W Notermans; F N J Frakking; S C de Greeff; T Leenstra
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-28       Impact factor: 3.267

Review 7.  [Gastrointestinal infections].

Authors:  C Lübbert; R Mutters
Journal:  Internist (Berl)       Date:  2017-02       Impact factor: 0.743

8.  The Human Gut Microbiome as a Transporter of Antibiotic Resistance Genes between Continents.

Authors:  Johan Bengtsson-Palme; Martin Angelin; Mikael Huss; Sanela Kjellqvist; Erik Kristiansson; Helena Palmgren; D G Joakim Larsson; Anders Johansson
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

9.  Management of Acute Diarrheal Illness During Deployment: A Deployment Health Guideline and Expert Panel Report.

Authors:  Mark S Riddle; Gregory J Martin; Clinton K Murray; Timothy H Burgess; Patrick Connor; James D Mancuso; Elizabeth R Schnaubelt; Timothy P Ballard; Jamie Fraser; David R Tribble
Journal:  Mil Med       Date:  2017-09       Impact factor: 1.437

Review 10.  Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report.

Authors:  Mark S Riddle; Bradley A Connor; Nicholas J Beeching; Herbert L DuPont; Davidson H Hamer; Phyllis Kozarsky; Michael Libman; Robert Steffen; David Taylor; David R Tribble; Jordi Vila; Philipp Zanger; Charles D Ericsson
Journal:  J Travel Med       Date:  2017-04-01       Impact factor: 8.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.